Genomics Inform.  2019 Sep;17(3):e23. 10.5808/GI.2019.17.3.e23.

Identification of neoantigens derived from alternative splicing and RNA modification

• Park J
• Chung YJ

• KMID: 2462037
• DOI: http://doi.org/10.5808/GI.2019.17.3.e23

Abstract

The acquisition of somatic mutations is the most common event in cancer. Neoantigens expressed from genes with mutations acquired during carcinogenesis can be tumor-specific. Since the immune system recognizes tumor-specific peptides, they are potential targets for personalized neoantigen-based immunotherapy. However, the discovery of druggable neoantigens remains challenging, suggesting that a deeper understanding of the mechanism of neoantigen generation and better strategies to identify them will be required to realize the promise of neoantigen-based immunotherapy. Alternative splicing and RNA editing events are emerging mechanisms leading to neoantigen production. In this review, we outline recent work involving the large-scale screening of neoantigens produced by alternative splicing and RNA editing. We also describe strategies to predict and validate neoantigens from RNA sequencing data.

Keyword

alternative splicing; neoantigen; RNA editing

MeSH Terms

Alternative Splicing*
Carcinogenesis
Humans
Immune System
Immunotherapy
Mass Screening
Peptides
RNA Editing
RNA*
Sequence Analysis, RNA
Peptides
RNA